Research Paper Volume 12, Issue 14 pp 14406—14417

Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway

Figure 5. osthole enhanced the cisplatin-induced apoptosis through the PTEN/AKT/Bad/Bcl-2 pathway in CD133+ HCC cells. (A) Effect of osthole (10 μmol/L) and PTEN siRNA on affecting the phosphorylation of AKT and Bad in CD133+ Huh7 and HepG2 cells. (B) Effect of osthole (10 μmol/L) and PTEN siRNA on affecting the interaction with Bad and Bcl-2 in CD133+ Huh7 and HepG2 cells. (C) Osthole (10 μmol/L) enhanced the effect of cisplatin (5 μmol/L) on reducing the mitochondrial membrane potential (ΔΨm) of CD133+ Huh7 and HepG2 cells. (D) Osthole (10 μmol/L) increased the cytosolic cytochrome c in CD133+ Huh7 and HepG2 cells which were treated with cisplatin (5 μmol/L). (E) Osthole (10 μmol/L) increased the apoptotic rate of CD133+ Huh7 and HepG2 cells which were treated with cisplatin (5 μmol/L).